Drug Delivery Approaches for Doxorubicin in the Management of Cancers

Abstract

Aim: We aimed to review the drug delivery approaches including novel drug delivery system of doxorubicin as an important anticancer drug. Background: Doxorubicin is widely used against breast, uterine, ovarian, lung and cervical cancer. It is listed among the essential medicines by WHO and is thus a very important drug that can be used to fight against cancer. Despite its effectiveness, the use of the drug is limited due to its dose-dependent toxicity. Several studies based on the Doxorubicin have been suggesting the need of novel drug delivery formulations in the treatment of malignant and cancerous diseases due to its cytotoxic nature. Objectives: This review focuses on the different formulations of doxorubicin which is a useful drug in the management of cancers, but associated with toxicity thus these approaches found applicability in the reduction of its toxicity. Methods: We searched the scientific database using cancer, doxorubicin, and different formulations as the keywords. Here in only peer-reviewed research articles collected which were useful to our current work. Conclusion: In the review, we described the significance of doxorubicin in the form of different delivery approaches in the management cancers with the reduction in the associated toxicity.

Advances of Layered Double Hydroxide‐Based Materials for Tumor Imaging and Therapy

“…[104] Doxorubicin (DOX), a broad-spectrum antitumor drug commonly used in clinical practice, has therapeutic effects on a wide range of tumors. [105] However, the cardiotoxicity associated with adriamycin has largely limited its clinical application. [106] li et al utilized MgAl-LDH as nanocarriers for the delivery of DOX.…”

Peptide-Based Supramolecular Hydrogels as Drug Delivery Agents: Recent Advances

“…The latter point can circumvent the problem of systemic toxicity of most chemotherapeutic drugs conventionally used, such as doxorubicin (DOX) [ 155 , 156 , 157 , 158 ]. This drug, in particular, causes irreversible damage to the myocardium, and therefore it is desirable to incorporate it into biomaterials, in order to increase its accumulation in tumour tissues, while reducing the associated side effects, without compromising its therapeutic efficiency [ 159 , 160 , 161 , 162 ]. As a drug used in the treatment of a wide range of cancers, DOX is often adopted as a model drug in investigations of nanosystems for drug delivery [ 159 ].…”

Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine

“…Ammonia, continuously produced by tumor cells during glutaminolysis, allows the efficient drug release at the site of the tumor [ 159 ]. Doxil was the first nanotherapeutic approved to treat cancer, and it is used for treating ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma [ 160 ]. It is also the first nanotherapeutic approved in the generic version under the name of Lipodox [ 161 ].…”